Madhavan Parasakthi, Sanjeev Kavitha
Dept. of Oral Pathology, SRM Dental College, Ramapuram campus, Chennai 600089, India.
Dept. of Conservative Dentistry and Endodontics, SRM Dental College, Ramapuram campus, Chennai 600089, India.
J Stomatol Oral Maxillofac Surg. 2025 Jun;126(3S):102184. doi: 10.1016/j.jormas.2024.102184. Epub 2024 Dec 7.
Oral cancer is always a global burden. It is the sixteenth most common cancer. It leads to metastasis since it is often diagnosed at late stages. To monitor the progress of this condition, various biomarkers are being utilized. Osteopontin is one such biomarker and its level in bodily fluids can be used as a reliable biomarker.
The current study aims to review and evaluate the prognostic role of osteopontin in oral squamous cell carcinoma.
A literature search was conducted across various databases such as Scopus, PubMed and Google Scholar. It yielded 18 articles totally using MeSH terms. The inclusion criteria were original research articles written only in English language involving both tissue and plasma osteopontin on oral cancer patients. Of these, only two articles which met the inclusion criteria were added into this systematic review. The search had no time restriction.
The studies showed that osteopontin play a vital role in the prognosis of the OSCC patients. One study from Taiwan and other from India proved the osteopontin expression in plasma and tissue can help to predict the prognosis of patients with oral cancer. Also, the level of plasma osteopontin was correlated with aggressiveness of OSCC. Tissue osteopontin expression was significantly lower in stage I OSCC patients when compared with stage II and III. Since there were only two studies, there is limited evidence of results.
From these findings, osteopontin can also be used as a reliable biomarker to predict the prognosis of oral cancer. Since there were only two studies to substantiate the finding, there is limited evidence and more studies are warranted to confirm the results.
口腔癌一直是一项全球性负担。它是第十六常见的癌症。由于其往往在晚期才被诊断出来,所以会导致转移。为了监测这种疾病的进展,人们正在使用各种生物标志物。骨桥蛋白就是这样一种生物标志物,其在体液中的水平可作为一种可靠的生物标志物。
本研究旨在回顾和评估骨桥蛋白在口腔鳞状细胞癌中的预后作用。
在Scopus、PubMed和谷歌学术等多个数据库中进行文献检索。使用医学主题词共检索到18篇文章。纳入标准为仅用英文撰写的涉及口腔癌患者组织和血浆骨桥蛋白的原创研究文章。其中,只有两篇符合纳入标准的文章被纳入本系统评价。检索无时间限制。
研究表明骨桥蛋白在口腔鳞状细胞癌患者的预后中起着至关重要的作用。一项来自台湾的研究和另一项来自印度的研究证明,血浆和组织中的骨桥蛋白表达有助于预测口腔癌患者的预后。此外,血浆骨桥蛋白水平与口腔鳞状细胞癌的侵袭性相关。与II期和III期相比,I期口腔鳞状细胞癌患者的组织骨桥蛋白表达明显较低。由于只有两项研究,结果的证据有限。
从这些发现来看,骨桥蛋白也可作为预测口腔癌预后的可靠生物标志物。由于仅有两项研究来证实这一发现,证据有限,需要更多研究来证实结果。